Risk models for predicting chemotherapy-induced neutropenia.
about
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideLipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsMultivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis.The effect of chemotherapy-induced anemia on dose reduction and dose delay.Impact of effective prevention and management of febrile neutropenia.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study.Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.Root caries risk indicators: a systematic review of risk models.Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropeniaIxabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancerPegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancerFebrile neutropenia in hematologic malignancies.Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumoursNeutropenia: occurrence and management in women with breast cancer receiving chemotherapyPharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.Febrile neutropenia in chemotherapy treated small-cell lung cancer patientsEpidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study.The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation.Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Trends in neutropenia-related inpatient events.Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL StudyNeutropenia and G-CSF in lymphoproliferative diseases.Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Granulocyte Colony-Stimulating Factor Use in a Large Iranian Hospital: Comparison with American Society of Clinical Oncology (ASCO) Clinical Practice GuidelineAgents under investigation for the treatment and prevention of neutropenia.Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.Management of chemotherapy-associated febrile neutropenia.The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.
P2860
Q26749476-E0A863E8-5557-47F2-B5C5-03F15FFA76A4Q26768126-8D28A08D-C26C-4F7F-9BF0-3B5120FC93E3Q33389472-7C2A9354-52F2-4DC5-9D98-A304F00675D6Q33403054-0C8D2B17-627D-4DA2-8E84-D8EDAE0CDE80Q33412051-287C889F-499B-4C32-8D3C-543D0BD0AD09Q33432161-890464EC-5DFF-4C99-B64B-D623A49C3829Q33503548-24E69644-4DFB-416A-BD7A-F0B38736CBC4Q33756369-89A09AE8-19DC-4C20-A59E-056ECBEC0627Q33778817-922A85A3-1DAE-4223-B947-B180E3CA7984Q34026627-F80A4FC7-F4E1-4E54-B874-06EE6E4F0325Q34233201-C78CA0AA-1CFD-4730-AF8A-D04EAED7F6C6Q34403621-14954943-EF30-4416-9ACD-9DF9697A1FFCQ34418413-AD58602F-DD1C-4B7D-AA1A-5605B266E24AQ34539360-0EAF6715-A659-427F-8790-03E302EDA4FDQ34553998-D26C077B-A91C-4163-9A62-37B922AA2300Q34580659-8EB791AD-02E7-4E3D-A0C9-55028467F1BEQ34613130-2287A04C-CB53-4276-8240-8C8A316C1ACEQ34655730-EB7F6818-25A9-4766-8F30-22F138CA3DBFQ34858123-3597848D-448C-4D24-85D8-3D2FBD7613B2Q34934481-9344E125-F39B-422D-8591-49326CA32413Q34996710-00D6A0DA-A02E-48D9-B414-7176BC968D41Q35297079-1EB94E18-6D36-4804-B874-82FE0988DF1FQ35753638-9BD0E187-5FA8-42C4-BCE5-26A0447B47A7Q35867279-34C9A409-2585-4B4B-AA6D-58218F0C998EQ36023851-237B4862-BBA0-4807-9297-6F4D32292CBFQ36095153-D8128B15-6162-42FA-A2B8-564AB60FCB8EQ36112023-602ABAA6-9022-4A4F-AF72-DC6417C78634Q36243957-3056C1CF-1A65-47FB-AC00-44EDF3983D47Q36828921-780DCF72-D0D0-4416-985C-D6CB265EC001Q36885665-560DDC5B-915B-46E3-AD33-8DE1A7E9B4DCQ36954388-BAF7DBD0-5C45-45BA-9278-24634012B57EQ36985881-F02F9A11-182C-41EB-BE23-250E97F786E3Q37264971-A3616C5F-911D-437A-95A8-F167B99E9644Q37320677-E88471B2-B511-4BA8-8BC6-0C4556B7E946Q37363344-9D3459FD-9416-4EA4-A7ED-795111E0D45BQ37607276-619D9991-98EE-419E-A723-558C71C01D98Q37831314-412B9FCD-03D2-415C-9903-0DBC9327A323Q37996443-632FB2B3-91AE-4646-BAE7-19C4C8396F4DQ38256944-ACD8815E-0AA7-4BC0-B138-127AD0E65019Q38269589-4D656B8C-752B-41E1-A936-60F376C16825
P2860
Risk models for predicting chemotherapy-induced neutropenia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Risk models for predicting chemotherapy-induced neutropenia.
@ast
Risk models for predicting chemotherapy-induced neutropenia.
@en
type
label
Risk models for predicting chemotherapy-induced neutropenia.
@ast
Risk models for predicting chemotherapy-induced neutropenia.
@en
prefLabel
Risk models for predicting chemotherapy-induced neutropenia.
@ast
Risk models for predicting chemotherapy-induced neutropenia.
@en
P2093
P1433
P1476
Risk models for predicting chemotherapy-induced neutropenia.
@en
P2093
Christopher H Lyman
Gary H Lyman
Olayemi Agboola
P304
P356
10.1634/THEONCOLOGIST.10-6-427
P577
2005-06-01T00:00:00Z